HLB Life Science acquires and cancels 600 million won worth of 13th series CBs... Conversion price (8,008 won) far above current price (3,370 won), limiting dilution risk
Due to the exercise of put option by bondholders, HLB Life Science acquired and will cancel 600 million won face value (612.18 million won including interest) of its 13th series unregistered private convertible bonds before maturity.
The remaining outstanding convertible bonds amount to 12.2 billion won with a conversion price of 8,008 won, significantly higher than the current stock price of 3,370 won, making conversion unlikely and limiting future dilution risk.
The acquisition was funded with internal cash, representing a passive liability management triggered by creditors rather than a proactive shareholder return policy.
[AI Comprehensive Analysis]This disclosure is a reactive debt management due to bondholder exercise, not a voluntary shareholder return. The cancellation scale is only about 4.7% of the total issue, having negligible impact on shareholder value. Given the lack of conversion incentive, this event is neutral for short-term stock price.
KOSDAQ Filing Information
Filing: Acquisition of Bonds Prior to Maturity Following Issuance of Convertible Bonds (Including Overseas Convertible Bonds) (Series 13)